The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review

• Published in: Virchows Archiv : an international journal of pathology Vol. 484; no. 2; pp. 369 - 375
• Main Authors: Lorkowski, Shuhui Wang, Dermawan, Josephine K., Rubin, Brian P.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2024; Springer Nature B.V
• Subjects: Algorithms; Artificial intelligence; Biomarkers; Cancer; Classification; Clinical trials; Copy number; Deep learning; Deoxyribonucleic acid; Diagnosis; Diagnostic systems; Digital imaging; DNA; DNA damage; DNA methylation; Gene expression; Immunotherapy; Learning algorithms; Machine learning; Medical diagnosis; Medical prognosis; Medicine; Medicine & Public Health; Melanoma; Metastases; Mutation; Oncology; Pathology; Patients; Precision medicine; Review and Perspectives; Tissues; Tobacco; Tumors; Methylomics; Cancer of unknown primary; Transcriptomics; Genomic profiling; Machine learning
• ISSN: 0945-6317; 1432-2307; 1432-2307
• DOI: 10.1007/s00428-023-03708-1

Cancer of unknown primary (CUP) presents a complex diagnostic challenge, characterized by metastatic tumors of unknown tissue origin and a dismal prognosis. This review delves into the emerging significance of artificial intelligence (AI) and machine learning (ML) in transforming the landscape of CUP diagnosis, classification, and treatment. ML approaches, trained on extensive molecular profiling data, have shown promise in accurately predicting tissue of origin. Genomic profiling, encompassing driver mutations and copy number variations, plays a pivotal role in CUP diagnosis by providing insights into tumor type-specific oncogenic alterations. Mutational signatures (MS), reflecting somatic mutation patterns, offer further insights into CUP diagnosis. Known MS with established etiology, such as ultraviolet (UV) light-induced DNA damage and tobacco exposure, have been identified in cases of dedifferentiated/transdifferentiated melanoma and carcinoma. Deep learning models that integrate gene expression data and DNA methylation patterns offer insights into tissue lineage and tumor classification. In digital pathology, machine learning algorithms analyze whole-slide images to aid in CUP classification. Finally, precision oncology, guided by molecular profiling, offers targeted therapies independent of primary tissue identification. Clinical trials assigning CUP patients to molecularly guided therapies, including targetable alterations and tumor mutation burden as an immunotherapy biomarker, have resulted in improved overall survival in a subset of patients. In conclusion, AI- and ML-driven approaches are revolutionizing CUP management by enhancing diagnostic accuracy. Precision oncology utilizing enhanced molecular profiling facilitates the identification of targeted therapies that transcend the need to identify the tissue of origin, ultimately improving patient outcomes.